



US009409975B2

(12) **United States Patent**  
**Hostetter et al.**

(10) **Patent No.:** US 9,409,975 B2  
(45) **Date of Patent:** Aug. 9, 2016

(54) **ANTIBODY BINDING MICROBIAL HEPARIN BINDING MOTIF TO RETARD OR PREVENT MICROBIAL BIOFILM FORMATION ON IMPLANTED MEDICAL DEVICES**

(71) Applicants: **Margaret K. Hostetter**, Cincinnati, OH (US); **Long Lu**, Cincinnati, OH (US); **Julianne Vernadette Green**, Cincinnati, OH (US); **Alexey Porollo**, Cincinnati, OH (US); **Kris I. Orsborn**, Terrace Park, OH (US); **Khoon Ghee Queenie Tan**, Durham, NC (US); **Kenneth Greis**, Fort Thomas, KY (US); **David Andes**, Madison, WI (US)

(72) Inventors: **Margaret K. Hostetter**, Cincinnati, OH (US); **Long Lu**, Cincinnati, OH (US); **Julianne Vernadette Green**, Cincinnati, OH (US); **Alexey Porollo**, Cincinnati, OH (US); **Kris I. Orsborn**, Terrace Park, OH (US); **Khoon Ghee Queenie Tan**, Durham, NC (US); **Kenneth Greis**, Fort Thomas, KY (US); **David Andes**, Madison, WI (US)

(73) Assignees: **Children's Hospital Medical Center**, Cincinnati, OH (US); **University of Cincinnati**, Cincinnati, OH (US); **Yale University**, New Haven, CT (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/518,051**

(22) Filed: **Oct. 20, 2014**

(65) **Prior Publication Data**

US 2015/0050284 A1 Feb. 19, 2015

**Related U.S. Application Data**

(63) Continuation-in-part of application No. PCT/US2013/031499, filed on Mar. 14, 2013.

(60) Provisional application No. 61/636,243, filed on Apr. 20, 2012.

(51) **Int. Cl.**

**A61K 31/00** (2006.01)  
**A61K 39/395** (2006.01)  
**C07K 16/00** (2006.01)  
**C07K 16/14** (2006.01)  
**C07K 16/12** (2006.01)  
**C07K 7/08** (2006.01)  
**A61K 39/00** (2006.01)

(52) **U.S. Cl.**

CPC . **C07K 16/14** (2013.01); **C07K 7/08** (2013.01);  
**C07K 16/1271** (2013.01); **A61K 39/00** (2013.01); **A61K 2039/505** (2013.01); **A61K 2039/575** (2013.01); **C07K 2317/34** (2013.01);  
**C07K 2317/76** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

5,886,151 A	3/1999	Hostetter et al.
6,346,411 B1 *	2/2002	Hostetter et al. .... 435/254.11
6,734,162 B2 *	5/2004	Van Antwerp ..... A61K 9/0019 514/6.3
6,774,219 B2 *	8/2004	Hostetter et al. .... 530/388.5
7,138,502 B2 *	11/2006	Hostetter et al. .... 530/388.5
7,241,613 B1 *	7/2007	Willins et al. .... 435/255.4
7,595,374 B1 *	9/2009	Chang et al. .... 530/330
2003/0082680 A1	5/2003	Hostetter et al.
2007/0116706 A1	5/2007	Hostetter et al.
2011/0189183 A1	8/2011	Williamson et al.

**FOREIGN PATENT DOCUMENTS**

DK WO 2006024631 A2 \* 3/2006 .... C07K 1/113

**OTHER PUBLICATIONS**

Brown et al. 1996 (Tolerance to single, but multiple, amino acid replacements in Antibody VH CDR2; J. Immunol. May;156(9):3285-91 at 3290.\*

Spear et al. Heparan sulfate glycosaminoglycans as primary cell surface receptors for herpes simplex virus. Adv. Exp Med Biol 313 (1992) 341-353.

International Search Report for PCT/US2013/31499, Jul. 9, 2013 (5 pages).

Written Opinion for PCT/US2013/31499, Jul. 9, 2013 (5 pages).

Advani et al. Central Line—Associated Bloodstream Infection in Hospitalized Children with Peripherally Inserted Central Venous Catheters: Extending Risk Analyses Outside the Intensive Care Unit. Clinical Infectious Diseases vol. 52, No. 9 (2011), pp. 1108-1115.

Alberti-Segui et al. Identification of potential cell-surface proteins in *Candida albicans* and investigation of the role of a putative cell-surface glycosidase in adhesion and virulence. Yeast, vol. 21 (2004), pp. 285-302.

Almirante et al. Epidemiology and Predictors of Mortality in Cases of *Candida* Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003. Journal of Clinical Microbiology, vol. 43, No. 4 (2005), pp. 1829-1835.

Alvarez-Dominguez et al. Host Cell Heparan Sulfate Proteoglycans Mediate Attachment and Entry of *Listeria monocytogenes*, and the Listerial Surface Protein ActA Is Involved in Heparan Sulfate Receptor Recognition. Infection and Immunity, vol. 65, no. (1997), pp. 78-88.

Andersson et al. Antimicrobial activities of heparin-binding peptides. Eur. J. Biochem. 271, 1219-1226 (2004).

Andes et al. Development and Characterization of an In Vivo Central Venous Catheter *Candida albicans* Biofilm Model. Infection and Immunity, vol. 72, No. 10 (2004), pp. 6023-6031.

(Continued)

*Primary Examiner* — Gary Nickol

*Assistant Examiner* — Mary Lyons

(74) *Attorney, Agent, or Firm* — Thompson Hine LLP

(57) **ABSTRACT**

Methods and reagents for ameliorating biofilm formation on a surface of an indwelling or implanted device in a patient resulting in decreased virulence of microorganisms such as *Candida* species and/or *Staphylococcus* species.